OncoMatch/Clinical Trials/NCT06211790
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Is NCT06211790 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Anlotinib, Everolimus and Tislelizumab for kidney cancer.
Treatment: Anlotinib, Everolimus and Tislelizumab — Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: PD-1/PD-L1 monoclonal antibody
Previously received PD-1/PD-L1 monoclonal antibody
Cannot have received: CTLA-4 antibody
Previously received ... CTLA-4 antibody(cytolytic T lymphocyte-associated antigen)
Cannot have received: immunotherapy
Previously received ... other immunotherapy
Cannot have received: targeted therapy
Previously received targeted therapy
Cannot have received: systemic therapy (radiation, surgery, chemotherapy, immunotherapy, molecular targeted therapy)
Exception: within the four weeks prior to treatment
Patients who have received the following medical interventions in the four weeks prior to treatment: Radiation, surgery, chemotherapy, immunotherapy or molecular targeted therapy for tumors
Lab requirements
Blood counts
HB ≥ 90 g/L; ANC ≥ 1.5 x 10^9/L; PLT ≥ 100 x 10^9/L (no blood transfusion or G-CSF within 14 days)
Kidney function
Serum creatinine ≤ 1.5× ULN or creatinine clearance ≥40 mL/min
Liver function
T-bil ≤1.5×ULN; ALT and AST≤2.5×ULN (≤5×ULN if liver metastasis)
Normal function of major organs ... Blood routine examination criteria ... Serum creatinine (Cr) ≤ 1.5× ULN or creatinine clearance ≥40 mL/min T-bil ≤1.5×ULN ... ALT and AST≤2.5×ULN If liver metastasis, ALT and AST≤5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06211790 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages